LGM Pharma Boosts Analytical Testing Services and Expands Suppository Manufacturing Capabilities
Source-lgmpharma LGM Pharma, a prominent provider of API and CDMO services, has unveiled significant advancements in its offerings aimed at enhancing customer flexibility and service efficiency. The company has invested over $2 million to expand its Analytical Testing Services (ATS) by 50% and has introduced new suppository manufacturing capabilities to its contract development and manufacturing (CDMO) portfolio. Enhanced Analytical Testing Services: LGM Pharma’s enhanced Analytical Testing Services cater to the diverse needs of pharmaceutical clients, ranging from major industry players to startups. The company boasts a comprehensive array of analytical testing capabilities for small-molecule drug substances and products, supported by state-of-the-art laboratories in Irvine, California. Equipped with cutting-edge chromatography and spectroscopy instrumentation, including ICP-MS and ICP-OES, LGM Pharma’s facilities exceed industry standards. The expanded analytic...